1. Home
  2. JBL vs ONC Comparison

JBL vs ONC Comparison

Compare JBL & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jabil Inc.

JBL

Jabil Inc.

HOLD

Current Price

$310.35

Market Cap

39.2B

Sector

Technology

ML Signal

HOLD

Logo BeiGene Ltd. American Depositary Shares

ONC

BeiGene Ltd. American Depositary Shares

HOLD

Current Price

$358.26

Market Cap

40.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JBL
ONC
Founded
1966
2010
Country
United States
Switzerland
Employees
N/A
12000
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.2B
40.6B
IPO Year
1999
2015

Fundamental Metrics

Financial Performance
Metric
JBL
ONC
Price
$310.35
$358.26
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
10
Target Price
$272.33
$385.10
AVG Volume (30 Days)
840.8K
321.3K
Earning Date
06-16-2026
05-06-2026
Dividend Yield
0.10%
N/A
EPS Growth
N/A
140.43
EPS
6.01
0.31
Revenue
$25,282,320,000.00
$238,387,000.00
Revenue This Year
$15.81
$723.76
Revenue Next Year
$9.76
$15.04
P/E Ratio
$50.72
$1,167.37
Revenue Growth
14.42
22179.16
52 Week Low
$189.60
$253.95
52 Week High
$428.93
$385.22

Technical Indicators

Market Signals
Indicator
JBL
ONC
Relative Strength Index (RSI) 41.55 57.05
Support Level $292.11 $325.47
Resistance Level $325.27 $375.97
Average True Range (ATR) 11.74 7.72
MACD -2.79 -3.12
Stochastic Oscillator 15.67 36.65

Price Performance

Historical Comparison
JBL
ONC

About JBL Jabil Inc.

Jabil Inc. is a U.S based company providing engineering, manufacturing, and supply chain solutions. It provides comprehensive electronics design, production, and product management services to companies in various industries and end markets. It operates through three segments: Regulated Industries, serving automotive, healthcare, and renewables; Intelligent Infrastructure, focused on AI, cloud, data centers, and communications, driving the majority of revenue; and Connected Living and Digital Commerce, specializing in digitalization and automation, such as robotics and warehouse automation. The company operates in the U.S., Mexico, China, Malaysia, Singapore, and several other markets.

About ONC BeiGene Ltd. American Depositary Shares

Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.

Share on Social Networks: